glp-1 medications market 2025 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Receptor Agonists Obesity Drugs

In WHOs VigiBase, which documented over 35 million cases, these drugs accounted for 118,639 instances (0.34%)

Common side effects include gastrointestinal issues, which lead to about 10% of patients discontinuing use, as well as risks like hypotension, pancreatitis, and the progression of diabetic retinopathy

In 2023, the state of Ohio secured a $110 million settlement with DuPont for PFAS contamination stemming from the Washington Works Plant

19 The corollary that sleep loss-induced delays in postprandial GLP-1 secretion might contribute to this effect is supported by the slight increase in post breakfast glucose concentrations that emerged in the TSD in comparison with the sleep condition of the present study, as reported previously

& Redmond, S